UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, DC 20549
FORM 8-K
CURRENT REPORT Pursuant
to Section 13 or 15(d) of the
Securities Exchange Act of 1934
Date of report (Date of earliest event reported) November 3, 2004
---------------------------
Interleukin Genetics, Inc.
--------------------------------------------------------------------------------
(Exact Name of Registrant as Specified in Its Charter)
Delaware
--------------------------------------------------------------------------------
(State or Other Jurisdiction of Incorporation)
000-23413 94-3123681
--------------------------------------------------------------------------------
(Commission File Number) (IRS Employer Identification No.)
135 Beaver Street Waltham, MA 02452
--------------------------------------------------------------------------------
(Address of Principal Executive Offices) (Zip Code)
(781) 398-0700
--------------------------------------------------------------------------------
(Registrant's Telephone Number, Including Area Code)
--------------------------------------------------------------------------------
(Former Name or Former Address, if Changed Since Last Report)
Check the appropriate box below if the Form 8-K filing is intended to
simultaneously satisfy the filing obligation of the registrant under any of the
following provisions (see General Instruction A.2. below):
|_| Written communications pursuant to Rule 425 under the Securities Act (17
CFR 230.425)
|_| Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR
240.14a-12)
|_| Pre-commencement communications pursuant to Rule 14d-2(b) under the
Exchange Act (17 CFR 240.14d-2(b))
|_| Pre-commencement communications pursuant to Rule 13e-4(c) under the
Exchange Act (17 CFR 240.13e-4(c))
Item 2.02 Results of Operations and Financial Condition.
On November 3, 2004, the Registrant issued a press release to report
its financial results for the quarter ended September 30, 2004. A copy of the
press release is attached hereto as Exhibit 99.1, which is incorporated in this
Item 2.02 by reference.
Item 9.01 Financial Statements and Exhibits.
(c) Exhibits.
Exhibit No. Description
---------- -----------
99.1 Press Release dated November 3, 2004.
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934,
the registrant has duly caused this report to be signed on its behalf by the
undersigned hereunto duly authorized.
Interleukin Genetics, Inc.
(Registrant)
Date: November 3, 2004 /s/ Fenel M. Eloi
-----------------------------
Fenel M. Eloi
Chief Operating Officer,
Chief Financial Officer,
Treasurer and Secretary